alleen voor onderzoeksdoeleinden

SAG (Smoothened Agonist) Hydrochloride Smoothened Agonist

Cat.nr.: S7779

SAG (Smoothened Agonist) HCl is een celpermeabele Smoothened (Smo)-agonist met een EC50 van 3 nM in Shh-LIGHT2-cellen.
SAG (Smoothened Agonist) Hydrochloride Hedgehog/Smoothened Agonist Chemical Structure

Chemische structuur

Molecuulgewicht: 526.52

Spring naar

Kwaliteitscontrole (Quality Control)

Batch: Zuiverheid: 99.98%
99.98

Celkweek, behandeling & werkzame concentratie
(Cell Culture, Treatment & Working Concentration)

Cellijnen Assaytype Concentratie Incubatietijd Formulering Activiteitsbeschrijving PMID
mouse Shh-Light II cell Function assay 48 hrs Activation of Shh pathway in mouse Shh-Light II cells assessed as induction of gli1 expression after 48 hrs by renilla luminescence assay, EC50=0.0088 μM 22985958
HUVEC Cytotoxicity assay 24 h Cytotoxicity against HUVEC after 24 hrs by WST-1 assay, IC50=22 μM 22985958
Shh-Light II Function assay 48 hrs Activation of Shh pathway in mouse Shh-Light II cells assessed as induction of gli1 expression after 48 hrs by renilla luminescence assay, EC50 = 0.0618 μM. 22985958
NIH/3T3 Function assay Agonist activity at Smo in mouse NIH/3T3 cells transfected with Gli-dependent firefly luciferase reporter assessed as stimulation of Gli transcription factor, EC50 = 0.03 μM. 27429255
C3H10T1/2 Function assay 6 days Agonist activity at Smo in mouse C3H10T1/2 cells assessed as induction of cell differentiation into osteoblast incubated for 6 days by alkaline phosphatase assay, EC50 = 0.13 μM. 27429255
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells 29435139
Saos-2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells 29435139
BT-37 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells 29435139
RD qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells 29435139
SK-N-SH qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells 29435139
BT-12 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells 29435139
MG 63 (6-TG R) qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells 29435139
NB1643 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells 29435139
OHS-50 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells 29435139
SJ-GBM2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells 29435139
NB-EBc1 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells 29435139
Rh18 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells 29435139
Klik om meer experimentele gegevens over cellijnen te bekijken

Chemische informatie, opslag en stabiliteit (Chemical Information, Storage & Stability)

Molecuulgewicht 526.52 Formule

C28H29Cl2N3OS

Opslag (vanaf de datum van ontvangst)
CAS-nr. 2095432-58-7 SDF downloaden Opslag van stamoplossingen

Synoniemen N/A Smiles CNC1CCC(CC1)N(CC2=CC(=CC=C2)C3=CC=NC=C3)C(=O)C4=C(C5=CC=CC=C5S4)Cl.Cl

Oplosbaarheid (Solubility)

In vitro
Batch:

DMSO : 82 mg/mL (155.73 mM)
(Met vocht verontreinigd DMSO kan de oplosbaarheid verminderen. Gebruik verse, watervrije DMSO.)

Water : 50 mg/mL

Ethanol : 27 mg/mL

Molariteitscalculator

Massa Concentratie Volume Molecuulgewicht
Verdunningscalculator Molecuulgewichtcalculator

In vivo
Batch:

In vivo formulatiecalculator (heldere oplossing)

Stap 1: Voer onderstaande informatie in (Aanbevolen: een extra dier om rekening te houden met verlies tijdens het experiment)

mg/kg g μL

Stap 2: Voer de in vivo formulering in (Dit is alleen de calculator, geen formulering. Neem eerst contact met ons op als er geen in vivo formulering is in de sectie oplosbaarheid.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Berekeningsresultaten:

Werkconcentratie: mg/ml;

Methode voor het bereiden van DMSO-moedervloeistof: mg geneesmiddel vooropgelost in μL DMSO ( Concentratie moedervloeistof mg/mL, Neem eerst contact met ons op als de concentratie de DMSO-oplosbaarheid van de batch van het geneesmiddel overschrijdt. )

Methode voor het bereiden van in vivo formulering: Neem μL DMSO moedervloeistof, voeg daarna toeμL PEG300, mengen en verhelderen, daarna toevoegenμL Tween 80, mengen en verhelderen, daarna toevoegen μL ddH2O, mengen en verhelderen.

Methode voor het bereiden van in vivo formulering: Neem μL DMSO moedervloeistof, voeg daarna toe μL Maïsolie, mengen en verhelderen.

Opmerking: 1. Zorg ervoor dat de vloeistof helder is voordat u het volgende oplosmiddel toevoegt.
2. Zorg ervoor dat u het/de oplosmiddel(en) in de juiste volgorde toevoegt. U moet ervoor zorgen dat de verkregen oplossing, bij de vorige toevoeging, een heldere oplossing is voordat u verdergaat met het toevoegen van het volgende oplosmiddel. Fysieke methoden zoals vortexen, ultrasoon of een warmwaterbad kunnen worden gebruikt om het oplossen te bevorderen.

Werkingsmechanisme (Mechanism of Action)

Targets/IC50/Ki
Smoothened
(mouse cultured cell assay)
3 nM(EC50)
In vitro

SAG regulates Smo activity by binding directly to the Smo heptahelical bundle.

SAG induces Smo-dependent signaling through Gli in a GRK2-dependent way.

SAG also (1 nM) induces proliferation of neuronal and glial precursors without affecting the differentiation pattern of newly produced cells.

Kinase Assay
Celgebaseerde assays voor Hh-routeactivering
Assays voor Hh-routeactivering in Shh-LIGHT2-cellen, een klonale NIH 3T3-cellijn die stabiel Gli-afhankelijke firefly-luciferase en constitutieve Renilla-luciferase-reporters incorporeert, worden uitgevoerd. Voor studies van SAG (een chloorbenzothiofeen-bevattende Hh-routeagonist) en PA-SAG worden Shh-LIGHT2-cellen gekweekt tot confluentie in 96-wells platen en vervolgens behandeld met verschillende concentraties van deze verbindingen in DMEM met 0,5% (vol/vol) runderkalfsserum.
In vivo

In the adult rat hippocampus, the intracerebroventricular administration of SAG (2.5 nM) significantly increases the number of newly generated cells and extends survival of hippocampal cells.

In mice, SAG (20 μg/g, i.p.) effectively prevents GC-induced neonatal cerebellar developmental abnormalities.

Referenties
  • [4] https://pubmed.ncbi.nlm.nih.gov/22013124/

Toepassingen (Applications)

Methoden Biomarkers Afbeeldingen PMID
Western blot LC3I / LC3II
S7779-WB1
23504944
Immunofluorescence acetylated alpha tubulin Smo
S7779-IF2
25992706

Informatie over klinische proeven (Clinical Trial Information)

(gegevens van https://clinicaltrials.gov, bijgewerkt op 2024-05-22)

NCT-nummer Werving Aandoeningen Sponsor/medewerkers Startdatum Fasen
NCT05937178 Recruiting
Hepatitis B Chronic
Huashan Hospital|The First Affiliated Hospital of Anhui Medical University|Anhui Provincial Hospital|Beijing YouAn Hospital|Peking University People''s Hospital|Peking University First Hospital|Xiamen Hospital of Traditional Chinese Medicine|First Affiliated Hospital of Fujian Medical University|LanZhou University|Third Affiliated Hospital Sun Yat-Sen University|First Affiliated Hospital of Guangxi Medical University|The Affiliated Hospital Of Guizhou Medical University|Hainan General Hospital|Hebei Medical University Third Hospital|The First Affiliated Hospital of Henan University of Traditional Chinese Medicine|Henan Provincial People''s Hospital|The Second Affiliated Hospital of Harbin Medical University|Tongji Hospital|Wuhan Union Hospital China|Renmin Hospital of Wuhan University|Central South University|Xiangya Hospital of Central South University|The First Hospital of Jilin University|the Second Hospital of Nangjing|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|The First Affiliated Hospital with Nanjing Medical University|The Affiliated Hospital of Xuzhou Medical University|The First Affiliated Hospital of Nanchang University|Shengjing Hospital|Qingdao Sixth People''s Hospital|Shandong Provincial Hospital|The Second Hospital of Shandong University|The First Affiliated Hospital of Shanxi Medical University|Tang-Du Hospital|First Affiliated Hospital Xi''an Jiaotong University|Ruijin Hospital|West China Hospital|Tianjin Second People''s Hospital|First Affiliated Hospital of Xinjiang Medical University|The First People''s Hospital of Yunnan|Shulan (Hangzhou) Hospital|Zhejiang University|Southwest Hospital China|The Second Affiliated Hospital of Chongqing Medical University|Sichuan Provincial People''s Hospital
2023-01-31 --
NCT05701592 Recruiting
Posterior Cruciate Ligament Tear
Konrad Malinowski MD|Artromedical Konrad Malinowski Clinic
2022-12-20 --
NCT06231056 COMPLETED
Genitourinary; Infection, Complicating Pregnancy
Liaquat University of Medical & Health Sciences
2019-01-01
NCT04165551 UNKNOWN
Streptococcus Agalactiae
Biosearch S.A.
2019-10-01 PHASE1
NCT03517943 COMPLETED
Clinical Pharmacology
Bayer
2018-04-24 PHASE1
NCT03517930 COMPLETED
Clinical Pharmacology
Bayer
2018-04-17 PHASE1